Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.11USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$5.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,748
52-wk High
$7.43
52-wk Low
$4.05

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $191.89
Shares Outstanding(Mil.): 37.55
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -1.76 -- --
ROI: -65.59 -0.75 13.17
ROE: -66.18 -2.86 14.98

BRIEF-Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update

* FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

28 Feb 2018

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

13 Feb 2018

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

03 Jan 2018

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

15 Nov 2017

Earnings vs. Estimates